Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Jennifer Abeles, DO

  • GBT 133 open label Inclacumab sickle cell. Jennifer Abeles (Co-Principal Investigator). Global Blood Therapeutics. 12/1/2022-3/1/2024.
  • GBT 132 - Single Dose Inclacumab for Sickle Cell VOC. Jennifer Abeles (Co-Principal Investigator). Global Blood Therapeutics. 12/1/2022-3/1/2024.

Christina Padgett, DO, MHS, FAAP

  • Development and Implementation of a Climate Change and Health Curriculum in a Pediatric Residency Program. Christina Padgett (Principal Investigator). New York State Children's Environmental Health Centers. 11/1/2022-11/1/2024.